StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a report released on Sunday morning. The brokerage issued a sell rating on the stock. Other analysts have also recently issued research reports about the company. Maxim Group cut their target price on Moleculin Biotech from $45.00 to $20.00 and set a […]
Moleculin Biotech (MBRX) Announces EMA Grants Orphan Drug Designation for Treatment of Acute Myeloid Leukemia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pharmaceutical company Moleculin Biotech, Inc. (MBRX) announced Thursday that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of Acute Myeloid Leukemia (AML).
The Philippine foreign trade deficit decreased in February from a year ago as exports grew more rapidly than imports, preliminary data from the Philippine Statistics Authority showed on Thursday.